Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacologic therapy for prostatism

M M Lieber1

  • 1Department of Urology, Mayo Clinic Rochester, Minnesota 55905, USA.

Mayo Clinic Proceedings
|June 11, 1998
PubMed
Summary
This summary is machine-generated.

Benign prostatic hyperplasia (BPH) management has shifted from surgery to medications like alpha-blockers and finasteride. These drugs effectively alleviate prostatism symptoms by relaxing prostate muscles or shrinking prostate volume.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytogenetics of prostate cancer.

International journal of urology : official journal of the Japanese Urological Association·2013
Same author

Hepatic Infarction.

The American journal of pathology·2009
Same author

Siderotic Nodules (Gandy-Gamna Bodies) in Primary Renal Carcinoma.

The American journal of pathology·2009
Same author

Intravascular extension of an osteosarcoma of the pubic bone into periprostatic venous plexus.

Urology·2005
Same author

Distribution of the Brief Male Sexual Inventory in community men.

International journal of impotence research·2003
Same author

Incidence of physician-diagnosed interstitial cystitis in Olmsted County: a community-based study.

BJU international·2003
Same journal

Thyroid Dysfunction and the Risk of Clinically Relevant Depression: A Longitudinal Cohort Study.

Mayo Clinic proceedings·2026
Same journal

37-Year-Old Woman With Jaundice.

Mayo Clinic proceedings·2026
Same journal

34-Year-Old Woman With An Unidentified Overdose.

Mayo Clinic proceedings·2026
Same journal

Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

Mayo Clinic proceedings·2026
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
See all related articles

Area of Science:

  • Urology
  • Pharmacology

Background:

  • Historically, transurethral resection of the prostate was the primary treatment for benign prostatic hyperplasia (BPH).
  • The advent of effective pharmacologic therapies has altered the initial management strategy for BPH and prostatism.

Purpose of the Study:

  • To review current pharmacologic treatment options for benign prostatic hyperplasia (BPH).
  • To describe the mechanisms of action and efficacy of available drug classes for prostatism.

Main Methods:

  • Review of selective alpha-adrenergic blocking agents (terazosin, doxazosin, tamsulosin).
  • Review of 5 alpha-reductase enzyme inhibitors (finasteride).

Main Results:

  • Alpha-adrenergic blockers relax prostate and bladder neck smooth muscle, improving voiding function within weeks.

Related Experiment Videos

  • Finasteride inhibits testosterone conversion to dihydrotestosterone, reducing prostate volume by ~25% over 12+ months.

    • Conclusions:

    • Pharmacologic therapies offer effective alternatives to surgery for managing BPH symptoms.
    • Continued development of new pharmacologic options is anticipated due to the growing aging male population with BPH.